

Atrium Health Infusion Center

Referral Status:	□ New Start □ Order Change □ Renewal
Preferred Location:	Atrium Health Infusion Center Concord Fax: 704-468-3401
	Atrium Health Infusion Center Pineville Fax: 704-468-3401
	Atrium Health Infusion Center Southpark Fax: 704-468-3401
	Atrium Health Infusion Center Huntersville Fax: 704-468-3401
	Atrium Health Infusion Center Kenilworth, a facility of CMC Fax: 704-512-5390
	Atrium Health Infusion Center Abbey Place, a facility of CMC Fax: 704-512-5390
	Atrium Health Infusion Center Cabarrus, a facility of CMC Fax: 704-512-5390

Ilumya® (tildrakizumab-asmn) Injection Order (Revised 10/16/2025)

All orders with a $$ will be placed.					
Patient Demographics:					
Patient Name:	Date of Bir	th:	MRN:		
Address:					
City:	State:		Zip Code:		
Allergies: (please list all allergies or attach list)					
□ NKDA					
Diagnosis: (Complete the 2nd and/or 3rd Digits of the	(CD-10)				
L40.0 - Psoriasis Vulgaris		Other:			
Required Documentation: (required prior to scheduli	ng)				
Patient Demographic Sheet		If the patient is new to the ordered therapy, indicate washout from previous therapy: No Washout Needed			
Copy of Insurance Card (front and back)					
Most Recent Labs (must include labs pertinent to medication ordered)					
Consult Note or last 2 Office Visits with referring provider or APP		If the patient is currently on the therapy, indicate date of last infusion:			
Complete Medication List -		Next infusion due date:			
Include all tried and failed meds		16.11			
Bis to a line De line De line Marine in Order de		If this is an ord	der change only, indicate if the current therapy should be administered until		
Diagnostic Studies Pertinent to Medication Ordered			☐ Yes ☐ No		
Treatment Parameters:					
Required Lab Results: PPD/Quantiferion Gold PRIOR to first injection (Fax labs with order)					
Notify provider IF: - PPD/Quantiferion Gold: POSITIVE result or not on file					
Nursing Communication:					
Allow syringe to sit at room temperature for 30 minutes prior to administration.					
Obtain vital signs PRE-injection and obtain vital signs POST-injection PRN.					
Monitor patient for signs of reaction for 30mins after completion of 1st injection and subsequent injections PRN if previous signs of reaction observed.					
Infusion Therapy:					
Tildrakizumab-asmn (Ilumya) 100mg SC week 0, week 4, then					
Tildrakizumab-asmn (Ilumya) 100mg SC every 12 weeks (84 days)					
Supportive Care Medications:					
Acetaminophen (Tylenol) 500mg PO every 4 hours PRN for mild pain (1-3), moderate pain (4-6). Give first.					
☑ Ibuprofen (Motrin) 800mg PO ONCE PRN for mild pain (1-3) or moderate pain (4-6). Give second after acetaminophen.					
Ondansetron (Zofran-ODT) 4mg PO every 3 hours PRN for nausea/vomiting.					
Hypersensitivity Protocol:					
Initiate Atrium Health approved hypersensitivity protocol in the event of an acute adverse or anaphylactic infusion/injection reaction. The hypersensitivity					
protocol can be found on the Atrium Health Infusion	n Center wel	osite at atriumhe	nealth.org/infusion.		
Prescriber Information:					
Provider Name:		Phone:	Fax:		
Practice Name:		NPI:			
Address:		Office Contact:			
City, State, Zip:		1	et Phone Number:		
Physician Signature: (Order expires 12 months from date of signature) No Stamp Signatures Accepted					
Signature:		Date:			